The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
Open accessPublished version of a preprint
Abstract
Only a fraction of patients with metastatic colorectal cancer receive clinical benefit from therapy with anti-epidermal growth factor receptor (EGFR) antibodies, which calls for the identification of novel biomarkers for better personalized medicine. We produced large xenograft cohorts from 85 patient-derived, genetically characterized metastatic colorectal cancer samples (“xenopatients”) to discover novel determinants of therapeutic response and new oncoprotein targets. Serially passaged tumors retained the morphologic and genomic features of their original counterparts. A validation trial confirmed the robustness of this approach: xenopatients responded to the anti-EGFR antibody cetuximab with rates and extents analogous to those observed in the clinic and could be prospectively stratified as responders or nonresponders on the basis of several predictive biomarkers. Genotype–response correlations indicated HER2 amplification specifically in a subset of cetuximab-resistant, KRAS/NRAS/BRAF/PIK3CA wild-type cases. Importantly, HER2 amplification was also enriched in clinically nonresponsive KRAS wild-type patients. A proof-of-concept, multiarm study in HER2-amplified xenopatients revealed that the combined inhibition of HER2 and EGFR induced overt, long-lasting tumor regression. Our results suggest promising therapeutic opportunities in cetuximab-resistant patients with metastatic colorectal cancer, whose medical treatment in the chemorefractory setting remains an unmet clinical need. Significance: Direct transfer xenografts of tumor surgical specimens conserve the interindividual diversity and the genetic heterogeneity typical of the tumors of origin, combining the flexibility of preclinical analysis with the informative value of population-based studies. Our suite of patient-derived xenografts from metastatic colorectal carcinomas reliably mimicked disease response in humans, prospectively recapitulated biomarker-based case stratification, and identified HER2 as a predictor of resistance to anti-epidermal growth factor receptor antibodies and of response to combination therapies against HER2 and epidermal growth factor receptor in this tumor setting. Cancer Discovery; 1(6); 508–23. ©2011 AACR. Read the Commentary on this article by Ciardiello and Normanno, p. 472 This article is highlighted in the In This Issue feature, p. 457
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HER2 overexpression is a negative predictor associated with reduced efficacy of anti-EGFR therapy [31], and >36% of cetuximab-resistant mCRC with wild-type KRAS, NRAS, BRAF, and PI3K was found to display HER2 overexpression [32].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [32]
In the citing paper
“A series of studies have demonstrated that HER2 gene amplification or activating mutations can mediate resistance to anti-EGFR mAbs in CRC [27,178,179].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [27]
In the citing paper
“Preclinical studies have shown that the combination of HER2 and EGFR blockade can lead to CRC tumor regression [27,28,29].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [27]
In the citing paper
“Two independent studies have recently shown that HER2 amplification is a predictor of poor sensitivity to anti-EGFR antibodies [91, 92].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [91]
In the citing paper
“In retrospective studies, patients with tumors featuring HER2 amplification or heregulin overexpression and treated with cetuximab or panitumumab experienced disease progression and shorter progression-free and overall survival compared with HER2 wild-type cases [91-93].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [91]
In the citing paper
“only the dual targeting of HER2 and EGFR by combining a small-molecule inhibitor, such as the dual EGFR/HER2 inhibitor lapatinib, with a moAb, such as cetuximab or pertuzumab, induced overt and long-lasting tumor regressions in proof-of-concept trials in HER2-amplified xenopatients [91].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [91]
In the citing paper
“Increased EGFR gene copy number could predict response among KRAS wild-type patients [53, 91, 111-113]”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [91]
In the citing paper
“Strong preclinical evidence suggests that dual inhibition of ERBB2 is superior to monotherapy due to enhanced efficacy and reduced therapy resistance4648”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [46]
In the citing paper
“Bertotti et al. identified ERBB2 as a biomarker of resistance to anti-EGFR mAbs [113].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [113]
In the citing paper
“A total of 2–7% of unselected CRCs were found to have ERBB2/mutations, and this number was much higher in KRAS wild-type cases (13.6%) and in KRAS/NRAS/BRAF/PIK3CA quadruple wild-type cases (36% )[13, 113, 114].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [113]
In the citing paper
“Finally, using patient-derived colon cancer xenografts, Bertotti et al. identified HER2 gene amplification as a predictor of resistance to cetuximab among KRAS wild-type tumors (Bertotti et al., 2011).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Bertotti et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Self-citationCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Self-citationUmar, A., Boland, C. R., Terdiman, J. P., Syngal, S., de la Chapelle, A., Rüschoff, J., Fishel, R. A., Lindor, N. M., Burgart, L. J., Hamelin, R., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh034 · Cited by 3,181
The Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Self-citationVan Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Self-citationCetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Cited by
Sorted by citations
Items 801–900 of 944
Biomarkers of colorectal cancer: A genome-wide perspective
Muñoz-Galván, S., & Santos-Pereira, J. M. (2016) · Cancer translational medicine · doi:10.4103/2395-3977.196911 · Cited by 1
Multiparameter Modalities for the Study of Patients in the Setting of Individualized Medicine
Miyabayashi, K., Tuveson, D. A., & Yu, K. H. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_65 · Cited by 1
Evans, D. M., & Teicher, B. A. (2017) · Molecular and translational medicine · doi:10.1007/978-3-319-57424-0_19 · Cited by 1
Fiori, A., Grand, A., Geda, E., Schioppa, D., Brundu, F. G., Mignone, A., & Bertotti, A. (2018) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-5225-3085-5.ch003 · Cited by 1
Self-citationMignone, A., Grand, A., Fiori, A., Médico, E., & Bertotti, A. (2019) · Database · doi:10.1093/database/baz080 · Cited by 1
Self-citationPossibilities of therapeutic use of HER2-inhibitorsin metastatic colorectal cancer: a case report
Качмазов, А. А., Болотина, Л. В., Kornietskaya, A. L., Васильевна, У. Т., Tolstov, V. A., & Феденко, А. А. (2019) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2019-19-126-131 · Cited by 1
Fiori, A., Grand, A., Alberto, P., Geda, E., Brundu, F. G., Schioppa, D., & Bertotti, A. (2017) · IGI Global eBooks · doi:10.4018/978-1-5225-3158-6.ch022 · Cited by 1
Self-citationTao, H., Shen, M., Zhang, X., Wang, M., Wu, Y., Sun, H., Chen, L., Yang, Y., Chen, K., & Li, D. (2022) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-22-1237 · Cited by 1
Recent Research Progress in Targeted Ther-apy of Metastatic Colorectal Cancer
张, 婷. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1361445 · Cited by 1
Probabilistic learning of treatment trees in cancer
Yao, T.-H., Wu, Z., Bharath, K., Li, J., & Baladandayuthapani, V. (2023) · The Annals of Applied Statistics · doi:10.1214/22-aoas1696 · Cited by 1
Zaboli, E., MajiMiriha, D. S., Naghshvar, F., Alizadeh‐Navaei, R., & HajiMiriha, M. S. (2023) · Tabari Biomedical Student Research Journal · doi:10.32598/tbsrj.v5i2.10530 · Cited by 1
Biomarkers and theranostics in colorectal cancer
Sabale, V., Dubey, S., Ingole, A. R., Shivhare, R. S., Godbole, M., & Sabale, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13870-6.00006-4 · Cited by 1
Grandes avances en el diagnóstico y tratamiento del cáncer colorrectal (CRC)
Jiménez, P., Canro, F., Bonilla, C., Ávila, V., & García‐Foncillas, J. (2024) · Medicina · doi:10.56050/01205498.2377 · Cited by 4
The current landscape of neoadjuvant therapy for resectable colon cancer
Chan, M., Krishnan, T., Townsend, A. R., Karapetis, C. S., Roy, A. C., Foo, T., Tebbutt, N. C., Dhillon, T., & Price, T. J. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2517881 · Cited by 1
A pan-cancer, pan-treatment model for predicting drug responses from patient-derived xenografts
Gupta, S., Mohani, V. K., Ghislat, G., Ballester, P. J., & Ahmad, S. (2025) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqaf111 · Cited by 1
Cardone, C., Martini, G., Troiani, T., Napolitano, S., Selvaggi, F., Ciardiello, F., & Martinelli, E. (2015) · Current Colorectal Cancer Reports · doi:10.1007/s11888-015-0278-1 · Cited by 1
The Complexity of Colorectal Cancer Biology — Putting Bricks on the Path to Personalized Medicine
Balboa, E., Carracedo, Á., & Barros, F. (2014) · InTech eBooks · doi:10.5772/57172 · Cited by 1
Genomic profiling of colorectal cancers and the future of personalized treatment
Harada, K., Kaya, D. M., Song, S., Baba, H., & Ajani, J. A. (2017) · Colorectal Cancer · doi:10.2217/crc-2016-0017 · Cited by 1
Patient-Derived Xenograft Models of Prostate Cancer
Marques, R. B., Ridder, C. M. A. D., & van Weerden, W. M. (2017) · Molecular and translational medicine · doi:10.1007/978-3-319-57424-0_8 · Cited by 1
20 YEARS OF TARGETING THERAPY OF SOLID TUMORS. SUCCESSES AND FAILURES
Tryakin, A. A., Fedyanin, M. Y., & Покатаев, И. А. (2018) · Practical oncology · doi:10.31917/1903183 · Cited by 1
ASCO 2021—an update on metastastic colorectal cancer
Weiß, L. (2021) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-021-00763-9 · Cited by 1
Mini-review: Antibody-PET of receptor tyrosine kinase interplay and heterogeneity
Chegu, A., Panikar, S. S., & Pereira, P. M. R. (2022) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2022.03.004 · Cited by 1
Sclafani, F., Roy, A. C., Chau, I., Wotherspoon, A. C., Peckitt, C., Dewdney, A., Oates, J. R., & Cunningham, D. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.e14616 · Cited by 1
Hanauske, A., & Hoff, D. D. V. (2017) · Holland‐Frei Cancer Medicine · doi:10.1002/9781119000822.hfcm053 · Cited by 1
Towards the era of precision medicine in metastatic colorectal cancer
Napolitano, S., Troiani, T., Martinelli, E., & Ciardiello, F. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000685 · Cited by 1
Repurposing Nelfinavir: AIM2 Inflammasome-Driven Anti-tumor Effects in GlioblastomaPreprint
Meena, D., Chhipa, S., Solanki, P., Sha, L., & Jha, S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.11.687819 · Cited by 1
Primary resistance to ATP-competitive mTOR inhibitors for the treatment of solid tumors
Ducker, G. S. (2013) · eScholarship (California Digital Library)
Cochrane, D. R., Lin, D., Dellaire, G., Halvorsen, E. C., Berman, J. N., Wang, Y., Huntsman, D. D., & Bennewith, K. L. (2014) · Cancer metastasis · doi:10.1007/978-3-319-12136-9_5
Identifying Actionable Targets in Cancer Patients
Uehling, D., Dancey, J. E., Brown, A. M. K., McPherson, J. D., & Al‐awar, R. (2013) · Methods and principles in medicinal chemistry · doi:10.1002/9783527677252.ch07
Fiori, A., Grand, A., Alberto, P., Geda, E., Brundu, F. G., Schioppa, D., & Bertotti, A. (2014) · Advances in healthcare information systems and administration book series · doi:10.4018/978-1-4666-6320-6.ch013
Self-citationRAS mutations: impact on treatment outcome
Mikhail, S., & Bekaii‐Saab, T. (2013) · Colorectal Cancer · doi:10.2217/crc.13.63
Troiani, T., Venturini, F., Napolitano, S., Martini, G., Gambardella, V., Ciardiello, F., & Martinelli, E. (2014) · Colorectal Cancer · doi:10.2217/crc.14.17
Mechanisms of resistance to EGFR inhibitors in colorectal cancers
Dhillon, T. (2014) · Colorectal Cancer · doi:10.2217/crc.14.37
Targeted Therapies For Intestinal Tumorigenesis
Chiorean, E. G., Coveler, A. L., Grim, J. E., & Grady, W. M. (2015) · Springer eBooks · doi:10.1007/978-3-319-19986-3_13
Elucidating the molecular aspects of colorectal cancer and their clinical importance
Sanz‐García, E., Marino, D., Élez, E., Macarulla, T. M., Capdevila, J., Alsina, M., Argilés, G., Saurí, T., & Tabernero, J. M. (2015) · Colorectal Cancer · doi:10.2217/crc.15.21
Personalisation of therapy in advanced colorectal cancer
Seligmann, J. (2015) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Zielgerichtetes Vorgehen gegen onkogene Faktoren
Zhao, Y., & Adjei, A. A. (2015) · Kompass Onkologie · doi:10.1159/000440780
Markers in Colorectal Cancer and Clinical Trials Based Upon Them
O’Hara, M. H., & O'Dwyer, P. J. (2015) · Current Colorectal Cancer Reports · doi:10.1007/s11888-015-0298-x
Styczen, H. (2013) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-4006
HER2検査における外部精度評価試料としての4-1ST xenograft model miceの有用性に関する検討
勝, 磯., 小山田裕行, 直樹, 島., Serizawa, A., 大西保行, & 健司, 川. (2016) · 医学検査 · doi:10.14932/jamt.15-54
Neues Target beim fortgeschrittenen kolorektalen Karzinom
Reinacher‐Schick, A. (2016) · Der Onkologe · doi:10.1007/s00761-016-0106-5
Resistance to Tyrosine Kinase Inhibitors in Different Types of Solid Cancer
Mirone, G., Perna, S., & Marfè, G. (2016) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-46091-8_2
Antibodies for Treatment of Metastatic Colorectal Cancer
Heinemann, V., & Stintzing, S. (2017) · Springer eBooks · doi:10.1007/978-3-319-43063-8_9
PDX Models of Colorectal Tumors
MacKeigan, J. P., & Burgenske, D. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804010-2.00021-7
Krebstherapie und Tumoransprechen
Hacker, U. T. (2017) · Forum · doi:10.1007/s12312-017-0248-4
Molecular Profiling in Colon Cancer: Where Are We Now?
Fratamico, R., & Cohen, S. J. (2017) · Current Colorectal Cancer Reports · doi:10.1007/s11888-017-0385-2
Molecular insights into the effects of cancer and chemotherapy on the brain
Kovalchuk, A. (2017)
Patient-Derived Xenografts for Research on Hormonal Therapy of Prostate Cancer
Inoue, T. (2018) · Springer eBooks · doi:10.1007/978-981-10-7013-6_4
Klampfer, L., & Owusu, B. Y. (2018) · doi:10.1002/9781119300229.ch2
Deciphering mechanisms of response and resistance in large-scale mouse cancer screens
Prahallad, A., Jensen, M. R., & Chapeau, E. A. (2019) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2019.02.006
Soveri, L. (2019) · Työväentutkimus Vuosikirja
New Approaches for the Treatment of Triple Negative Breast Cancer
Sulaiman, A. (2019) · uO Research (University of Ottawa) · doi:10.20381/ruor-23348
Murakami, M. A. (2016) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Zhang, P., & Kovtun, I. V. (2020) · Journal of Visualized Experiments · doi:10.3791/60646
Mapping the Radiogenome of Human Cancers
Gopal, P., Castrillon, J. A., & Abazeed, M. E. (2020) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-030-49701-9_3
Precision Medicine in Metastatic Colorectal Cancer—Finding and Hitting the Right Targets
Ciombor, K. K., & Bekaii‐Saab, T. (2020) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2020.16.1.36
Development of HER2 -targeted Therapies for Gastrointestinal Cancer
Sawada, K., Nakamura, Y., & Shitara, K. (2020) · European Oncology & Haematology · doi:10.17925/eoh.2020.16.1.29
In vivo animal models for cancer: What have we learned from chemical-induced and xenograft models
Jain, S., Raza, K., Agrawal, A. K., & Vaidya, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817846-1.00028-x
FGFR-Alterationen in primären und oligometastasierten kolorektalen Karzinomen
Fromme, J. E. (2020) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8291
Lesmana, V. A. (2020) · Jurnal Kedokteran RAFLESIA · doi:10.33369/juke.v6i2.13785
Three-dimensional Hyaluronan-based Hydrogels Designed for Breast Cancer Spheroid Formation
Baker, A. E. G. (2019) · TSpace (University of Toronto)
Novel Biomarker-Targeted Therapies for Metastatic Colorectal Cancer
Barot, S. V., & Kamath, S. D. (2021) · Digestive Disease Interventions · doi:10.1055/s-0041-1727225
GLUD1 Promotes Cetuximab Resistance in Metastasis Colorectal CancerPreprint
Peng, K., Xu, X., Liu, M., Liang, L., Yuan, Y., Hou, Y., Yu, Y., & Liu, T. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3907832
Current Treatment Landscape for Third- or Later-Line Therapy in Metastatic Colorectal Cancer
Qureshi, S., Berim, L. D., & Boland, P. M. (2021) · Current Colorectal Cancer Reports · doi:10.1007/s11888-021-00469-4
Molecularly targeted therapy in metastatic CRC
Bañobre, J. R., Brozos-Vázquez, E., Vázquez-Rivera, F., Vidal-Ínsua, Y., López‐López, R., & Folgar, S. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90055-3.00028-4
How to overcome resistance to therapy?
Qvortrup, C., Tejpar, S., & Pfeiffer, P. (2012) · PubMed Central · doi:10.3978/j.issn.2078-6891.2012.015
Wiedmann, S. (2022) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-43
Chemoresistance and metastasis in colorectal cancer
Wong, S. Q. R. (2022) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/155418
Patient samples used to determine therapy combinations
(2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.155
Multiparameter Modalities for the Study of Patients in the Setting of Individualized Medicine
Miyabayashi, K., Tuveson, D. A., & Yu, K. H. (2017) · Springer eBooks · doi:10.1007/978-1-4939-6631-8_65-1
Evolving Role of Circulating Tumor DNA and Emerging Targeted Therapy in Colorectal Cancer
Malla, M., & Parikh, A. R. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.02.009
Prädiktive Testung von Tumorgewebe und ihre klinischen Konsequenzen
Hoffmann, J. (2022) · Springer Reference Medizin · doi:10.1007/978-3-662-46764-0_148-1
Role of dual anti-HER2 therapy before liver resection for rectal metastases
Dantu, S., Khan, A., & Dhir, M. (2022) · Journal of Surgical Case Reports · doi:10.1093/jscr/rjac420
Prognostische und prädiktive Biomarker beim kolorektalen Karzinom
Stintzing, S., & Jelas, I. (2022) · Trillium Diagnostik · doi:10.47184/td.2022.03.03
Li, G., Tian, L., Fu, W., Lei, C., & Hu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821584-5.00026-2
Ma, Z., Lei, C., & Hu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821584-5.00021-3 · Cited by 1
Li, G., Lei, C., & Hu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821584-5.00029-8
Gohel, S., & Lavingia, V. K. (2023) · International Journal of Molecular and Immuno Oncology · doi:10.25259/ijmio_30_2022
Clinical, Pathological, and Molecular Characteristics in Colorectal Cancer
Dedieu, S. (2023) · MDPI eBooks · doi:10.3390/books978-3-0365-6836-2
Meric‐Bernstam, F., Johnson, A. M., Dumbrava, E. E. I., Raghav, K. P. S., Balaji, K., Bhatt, M., Murthy, R. K., Rodon, J. A., & Piha-Paul, S. A. (2023) · doi:10.1158/1078-0432.c.6528374.v1
Leto, S. M., Ferri, M., Sassi, F. P., Zanella, E. R., Cottino, F., Vurchio, V., Catalano, I., Ferrero, A., Zingaretti, C. C., Marchiò, C., et al. (2023) · doi:10.1158/1078-0432.c.6533128.v1
Self-citationLuraghi, P., Reato, G., Cipriano, É., Sassi, F. P., Orzan, F., Bigatto, V., Bacco, F. D., Menietti, E., Han, M., Rideout, W. M., et al. (2023) · doi:10.1158/0008-5472.22402016
Self-citationLuraghi, P., Reato, G., Cipriano, É., Sassi, F. P., Orzan, F., Bigatto, V., Bacco, F. D., Menietti, E., Han, M., Rideout, W. M., et al. (2023) · doi:10.1158/0008-5472.22402016.v1
Self-citationWilliams, C. J. M., Seligmann, J. F., Elliott, F., Shires, M., Richman, S. D., Brown, S., Zhang, L., Singh, S., Pugh, J., Xu, X., et al. (2023) · doi:10.1158/1078-0432.c.6529961
Lafferty, A., O’Farrell, A. C., Migliardi, G., Khemka, N., Lindner, A. U., Sassi, F. P., Zanella, E. R., Salvucci, M., Vanderheyden, E., Modave, E., et al. (2023) · doi:10.1158/1078-0432.c.6530519
Self-citationData from Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas
Corso, S., Pietrantonio, F., Apicella, M., Migliore, C., Conticelli, D., Petrelli, A., D’Errico, L., Durando, S., Moya-Rull, D., Bellomo, S. E., et al. (2023) · doi:10.1158/1078-0432.c.6530756
Self-citationSerra-Camprubí, Q., Verdaguer, H., Oliveros, W., Lupión-Garcia, N., Llop‐Guevara, A., Molina, C., Vila-Casadesús, M., Turpin, A., Neuzillet, C., Frigola, J., et al. (2023) · doi:10.1158/1078-0432.c.6532853
Lafferty, A., O’Farrell, A. C., Migliardi, G., Khemka, N., Lindner, A. U., Sassi, F. P., Zanella, E. R., Salvucci, M., Vanderheyden, E., Modave, E., et al. (2023) · doi:10.1158/1078-0432.c.6530519.v1
Self-citationSerra-Camprubí, Q., Verdaguer, H., Oliveros, W., Lupión-Garcia, N., Llop‐Guevara, A., Molina, C., Vila-Casadesús, M., Turpin, A., Neuzillet, C., Frigola, J., et al. (2023) · doi:10.1158/1078-0432.c.6532853.v1
Jacobs, S. A., Lee, J. J., George, T. J., Wade, J. L., Stella, P. J., Wang, D., Sama, A. R., Piette, F., Pogue–Geile, K. L., Kim, R. S., et al. (2023) · doi:10.1158/1078-0432.c.6530607.v1
Williams, C. J. M., Seligmann, J. F., Elliott, F., Shires, M., Richman, S. D., Brown, S., Zhang, L., Singh, S., Pugh, J., Xu, X., et al. (2023) · doi:10.1158/1078-0432.c.6529961.v1
Rau, A., Janssen, N., Kühl, L., Sell, T., Kalmykova, S., Mürdter, T. E., Dahlke, M., Sers, C., Morkel, M., Schwab, M. G., et al. (2023) · doi:10.1158/1535-7163.c.6543369
Rau, A., Janssen, N., Kühl, L., Sell, T., Kalmykova, S., Mürdter, T. E., Dahlke, M., Sers, C., Morkel, M., Schwab, M. G., et al. (2023) · doi:10.1158/1535-7163.c.6543369.v1
Jo, H., Yagishita, S., Hayashi, Y., Ryu, S., Suzuki, M., Kohsaka, S., Ueno, T., Matsumoto, Y., Horinouchi, H., Ohe, Y., et al. (2023) · doi:10.1158/1535-7163.c.6543219.v1
Jo, H., Yagishita, S., Hayashi, Y., Ryu, S., Suzuki, M., Kohsaka, S., Ueno, T., Matsumoto, Y., Horinouchi, H., Ohe, Y., et al. (2023) · doi:10.1158/1535-7163.c.6543219
Peng, P., Qiang, X., Li, G., Li, L., Ni, S., Yu, Q., Sourd, L., Marangoni, E., Hu, C., Wang, D., et al. (2023) · doi:10.1158/1535-7163.22523254
Target Hyperactive ERK Signaling for Cancer Therapy
Yap, J., & Hu, J. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_257-1
Data from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
Petrelli, A., Rizzolio, S., Pietrantonio, F., Bellomo, S. E., Benelli, M., Cecco, L. D., Romagnoli, D., Berrino, E., Orrù, C., Ribisi, S., et al. (2023) · doi:10.1158/0008-5472.c.6626691.v1
Self-citationAlonazi, F. N., Hawsawi, Y. M., Alanazi, H. G., Alqarni, A. M., Alghamdi, S. A., & Alanazi, R. J. (2024) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815196382124010004
Vangala, D., Ladigan, S., Liffers, S. T., Noseir, S., Maghnouj, A., Götze, T.-M., Verdoodt, B., Klein‐Scory, S., Godfrey, L., Zowada, M. K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14998919
Metadata
- Authors
- Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., Ribero, D., Russolillo, N., Muratore, A., Massucco, P., Pisacane, A., Molinaro, L., Valtorta, E., Sartore-Bianchi, A., Risio, M., Capussotti, L., Gambacorta, M., Siena, S., Medico, E., Sapino, A., Marsoni, S., Comoglio, P. M., Bardelli, A., & Trusolino, L.
- Affiliations
- IFOM (IT)
- Authors' Affiliations: 1Laboratory of Molecular Pharmacology, 2Laboratory of Oncogenomics, 3Laboratory of Systems Biology, 4Laboratory of Molecular Genetics, 5Division of Surgical Oncology, 6Unit of Pathology, 7Clinical Coordination Unit, and 8Molecular Clinical Oncology, Institute for Cancer Research and Treatment, Torino; Departments of 9Oncological Sciences and 10Biomedical Sciences and Human Oncology, University of Torino Medical School, Torino; 11Department of Surgery, Mauriziano Umberto I Hospital, Torino; 12FIRC Institute of Molecular Oncology, Milano; 13Division of Pathology, 14Falck Division of Medical Oncology, Ospedale Niguarda Ca' Granda, Milano; and 15Southern Europe New Drug Organization Foundation, Milano, Italy
- ORCID
- Venue
- Cancer Discovery
- Published
- 2011-11-01
- Volume
- 1
- Issue
- 6
- Pages
- 508-523
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W1987443121
- Cited by
- 939
- References
- 56
- Citations by year
- 2026: 24 · 2025: 42 · 2024: 46 · 2023: 79 · 2022: 72 · 2021: 74 · 2020: 71 · 2019: 86 · 2018: 86 · 2017: 90 · 2016: 71 · 2015: 62 · 2014: 60 · 2013: 48 · 2012: 23
- FWCI
- 21.44
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Associazione Italiana per la Ricerca sul Cancro
- Regione Piemonte
- Genentech
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- patient-derived xenografts, metastatic colorectal cancer, cetuximab resistance, HER2 amplification, anti-EGFR therapy, predictive biomarkers, combination therapy, KRAS wild-type, BRAF wild-type, treatment resistance, tumor heterogeneity
- MeSH terms
- Cetuximab, Aged, Aged, 80 and over, Animals, Antibodies, Monoclonal, Female, Humans, Male, Mice, Inbred C57BL, Mice, Transgenic, Middle Aged, Prospective Studies, Biomarkers, Tumor, Colorectal Neoplasms, ras Proteins, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Mice, Molecular Targeted Therapy, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
